Arkayli Biopharma, Inc.
Publicly observedTracys Landing, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Tracys Landing | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Arkayli Biopharma, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | Y569SLYB1EJ9 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant20 Sept 2026Publicly observed
NIH SBIR/STTR award: Clinical Development of ARK001 Formulation as a Targeted Therapeutic for InfantileHemangioma
USD 999,904.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jun 2025Publicly observed
NIH SBIR/STTR award: Developing a topical beta blocker formulation as a targeted therapeutic for infantile hemangioma
USD 306,804.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.